Zentiva Launches First Biosimilar Monoclonal Antibody Across EU
Zentiva has launched its first biosimilar monoclonal antibody across the European Union after receiving approval from the European Medicines Agency, announced in a press release.
The biosimilar is used for treating bone-related diseases and was approved through the EMA's centralized procedure. Distribution to European markets will begin in December 2025.
This marks Zentiva's entry into the biosimilars segment as part of its broader strategy to expand beyond traditional generics. The company stated that the move supports sustainable growth in the biologics sector, one of the fastest-growing areas in pharmaceuticals.
We hope you enjoyed this article
Consider subscribing to one of our newsletters like Life AI Weekly or Daily AI Brief.
Also, consider following us on social media:
More from Life Sciences
Nov 13 Bracco and Avicenna.AI win FDA clearance for AI that flags brain aneurysms on CT scans Nov 13 Zus Health raises $33 million to build the data layer for healthcare AI Nov 13 Google DeepMind releases AlphaGenome 2 to predict DNA variant effects in specific cell types Nov 13 Taiwan hospital accelerator T+ MedIC names AI ECG and CT screening tools as first winners Nov 13 Sheinbaum meets OpenAI president Greg Brockman on AI in Mexican healthcareLife AI Weekly
Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.
Whitepaper
Tensordyne Napier: What If One Rack Could Do the Work of Nine?
Tensordyne
This Tensordyne whitepaper presents Napier, an inference-focused AI processor and rack-scale system based on the company’s TDN Math logarithmic number system. It examines infrastructure requirements for large mixture-of-experts and agentic models, compares major inference architecture approaches, and details the TDN AIP processor, TDN72 pod, TDN Link fabric, and Napier Ultra configuration. The paper reports simulation-based performance, cost, and accuracy-validation results, including Tensordyne’s projected comparison of one Napier rack with a nine-rack Nvidia Rubin plus Groq deployment; the chip is reported as taped out and in fabrication.
Read moreYou may also like
Lunit and Summit Test AI Pathology for Ivonescimab Research
Flagship Pioneering Merges Three Biotech Platforms Into Etcelera
Switchpoint Bio raises $5.3 million for AI epigenomics platform
Zealand Pharma signs AI obesity drug deal worth up to $1.2 billion
Atlas Bio raises $12.5 million for virtual drug trials
Daily AI Brief: the AI news that matters, in your inbox.